Stay updated with breaking news from Nasdaq Howl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research report issued on Monday, RTT News reports. They presently have a $9.00 target price on the stock. Wedbush’s target price points to a potential upside of 50.50% from the company’s previous close. Other equities […]
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a report issued on Monday, RTT News reports. They presently have a $9.00 price objective on the stock. Wedbush’s target price indicates a potential upside of 50.50% from the stock’s current price. A number of other […]
Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) was down 2.2% on Tuesday . The company traded as low as $2.48 and last traded at $2.62. Approximately 102,646 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 337,653 shares. The stock had previously closed at $2.68. Wall Street […]
– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of...
Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 318,400 shares, a growth of 562.0% from the October 15th total of 48,100 shares. Based on an average trading volume of 809,800 shares, the short-interest ratio […]